Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Venkatesh Pilla-Reddy

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Schizophrenia Research|March 12, 2013
Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utilityVenkatesh Pilla Reddy, Magdalena Kozielska, Ahmed Abbas Suleiman, et al.
Clinical Pharmacokinetics|March 17, 2012
Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trialsVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Pharmaceutical Research|May 6, 2014
Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approachMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Schizophrenia Research|March 12, 2013
Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS scoreVenkatesh Pilla Reddy, Magdalena Kozielska, Ahmed Abbas Suleiman, et al.
Pharmaceutical Research|January 1, 2016
Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor OccupancyMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Journal of Clinical Psychopharmacology|October 12, 2013
Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scaleVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Molecular Pharmaceutics|June 7, 2023
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell ProteomeMatthew D Harwood, Katharina Zettl, Manuel Weinheimer, et al.
Drug Design, Development and Therapy|September 15, 2018
Asenapine pharmacokinetics and tolerability in a pediatric populationPeter Dogterom, Robert Riesenberg, Rik de Greef, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 30, 2011
Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokineticsRamesh Jayaraman, Venkatesh Pilla Reddy, Mohammed Khalid Pasha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GISTVenkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Schizophrenia Research|March 12, 2013
Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utilityVenkatesh Pilla Reddy, Magdalena Kozielska, Ahmed Abbas Suleiman, et al.
Clinical Pharmacokinetics|March 17, 2012
Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trialsVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Pharmaceutical Research|May 6, 2014
Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approachMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Schizophrenia Research|March 12, 2013
Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS scoreVenkatesh Pilla Reddy, Magdalena Kozielska, Ahmed Abbas Suleiman, et al.
Pharmaceutical Research|January 1, 2016
Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor OccupancyMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Journal of Clinical Psychopharmacology|October 12, 2013
Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scaleVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Molecular Pharmaceutics|June 7, 2023
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell ProteomeMatthew D Harwood, Katharina Zettl, Manuel Weinheimer, et al.
Drug Design, Development and Therapy|September 15, 2018
Asenapine pharmacokinetics and tolerability in a pediatric populationPeter Dogterom, Robert Riesenberg, Rik de Greef, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 30, 2011
Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokineticsRamesh Jayaraman, Venkatesh Pilla Reddy, Mohammed Khalid Pasha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GISTVenkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
Pageof 6